$2.2 billion in ACA subsidies are coming back to taxpayers. 🔥 That number should stop everyone in healthcare in their tracks. On September 22, CMS announced it is canceling approximately 315,000 unauthorized enrollments in the Federal Health Insurance Marketplace, covering more than 760,000 individuals. According to the CMS press release, the agency expects this action to result in the return of roughly $2.2 billion in taxpayer-funded subsidies. Let that sink in for a second. 760,000 people. One enforcement action. $2.2 billion. This is not a small audit finding. This is a systemic failure in how the Marketplace was being administered, and it has been hiding in plain sight. 🔹 Since January 2026, CMS has issued termination notices for over 200 ...

70% of cancer deaths come from cancers with no recommended screening test. 🧬 That number stopped me cold when I read it in USA Today this week. We talk a lot about improving lung cancer screening rates. About getting more people into the pipeline for the five cancers that already have established screening. And that work is urgent and necessary. But 70% of cancer deaths are happening completely outside that pipeline. This week, the FDA's Molecular and Clinical Genetics Devices Panel voted in favor of GRAIL's Galleri multi-cancer early detection blood test. The vote on whether benefits outweigh risks: 7 to 2, with one abstention. The safety vote was unanimous. Here is what Galleri actually does: 🔹 It studies DNA ...

CFO, are you paying for a law that was supposed to protect your employees? 💥 Because that is exactly what is happening right now. This week, a coalition of 67 health care industry and advocacy groups sent a letter to congressional leadership calling the No Surprises Act arbitration process a "massive unforeseen crisis in employer-sponsored coverage." Those words belong to Melissa Bartlett, senior vice president for health policy at the ERISA Industry Committee. She is not a fringe voice. She speaks for the people managing the benefits your employees depend on. Here is what went wrong. The No Surprises Act, passed in 2020, did something genuinely good. It shielded patients from getting blindsided by out-of-network bills. That part worked. But ...

Europe just made a $100M bet that AI owns the clinic. 🏥 And the signal is bigger than the check. According to The Next Web, Tandem Health closed a $100m Series B led by the Scaleup Europe Fund, managed by EQT. Existing investors Kinnevik, Northzone, Amino Collective, and Visionaries joined the round. This brings the Stockholm-based company's total funding to $160m, following a $50m Series A in 2025. Here is what makes this round worth paying attention to. The Scaleup Europe Fund is an EU-backed vehicle. This is its first healthcare investment. Ever. When a sovereign-backed fund of that profile plants its first healthcare flag in a clinical AI company, that is not a portfolio decision. That is a policy ...

A radiation oncologist in a rural freestanding center opens the 2026 payment summary. CMS said the cut would be 1%. The actual number on the screen is 22%. That gap is not a rounding error. It is a structural failure with real consequences for cancer access. According to Newswise, citing an ASTRO statement submitted to CMS on September 14, 2026, more than two-thirds of radiation oncologists responding to an ASTRO survey reported payment declines of 10% or more following coding and payment changes implemented January 1. Many reported cuts of 20% to 30%. CMS had projected an overall reduction of just 1%. That is not a forecast miss. That is a policy credibility problem. I call this the Radiation Oncology ...

More patients. Less revenue. Same legal obligation to serve everyone. 🏥 Most people think Medicaid cuts mean fewer patients walk through the doors of community health centers. The opposite is true. According to Charta Health, FQHCs serve approximately 32 million patients annually, and Medicaid and CHIP accounts for roughly half of total patient volume. When coverage contracts, the patients do not disappear. They lose their insurance cards, then come back as uninsured or sliding-fee visits. The cost-to-serve stays exactly the same. The revenue does not. Section 330 of the Public Health Service Act is unambiguous: federally qualified health centers must serve every patient regardless of ability to pay. That mission mandate does not flex with policy shifts. That is the ...

The FDA just funded a jury of AI judges for radiology reports. 🧠 Not one AI. A panel of them. Cross-examining each other. Last week, the FDA awarded Cognita Imaging a $1.29 million research contract to build what they call an "LLMs-as-a-jury" evaluation framework for autonomous, generative AI radiology reports. According to HIT Consultant, the 18-month contract was funded under the FDA's Broad Agency Announcement program for advanced research and development in regulatory science. Here is why this matters to anyone building in this space. 🔹 Traditional human reader studies evaluate only a few hundred cases. 🔹 They miss rare edge cases, subtle equipment discrepancies, and regional workflow variations. 🔹 Cognita's framework will be stress-tested across approximately 1 million patient ...

Texas hospitals were bleeding $27 million a day. That just ended. 🏥 On September 17, Governor Greg Abbott announced that nearly $12 billion in Medicaid funding would be restored to Texas hospitals, ending a near year-long standoff with the federal government. This wasn't a minor bureaucratic dispute. According to KERA News, this was the first time CMS had stopped supplemental Medicaid funding to Texas hospitals since that funding began in 2014. Let that land for a second. The halt started September 1, the beginning of Texas's new fiscal year. Hospitals across the state, including rural clinics, nursing facilities, behavioral health providers, and emergency rooms, were operating under that $27 million per day drain. What actually caused this? 🔹 Texas raises ...

Everyone is calling multi-cancer blood tests a breakthrough. They are missing the real story. 🔬 The hype is real. But so is the gap it exposes. According to Duke Today, we currently have early screening tests for exactly five types of cancer: breast, colorectal, prostate, cervical, and lung. And every single one of those tests screens for only one cancer at a time. That is the baseline we have been working from. Now MCED tests, multi-cancer early detection, change the math entirely. 🔹 A single tube of blood can screen for up to 50 cancers. 🔹 The test detects cancer cells floating in the blood. 🔹 A positive result can identify the mutation within the DNA and the site of ...